1) Radionuclide therapy
Treatment of bone metastasis in prostate cancer with radium chloride (Ra-223) (SPECT / CT)

Radium chloride (Ra-223, Xofigo) is used as a treatment of bone metastasis in prostate cancer.
In standard protocol, the dose is determined by body weight. However, it has been reported that distribution of Ra-223 in the bone metastatic lesion is variable from patient to patient.
By capturing the gamma rays emitted from Ra-223, whole-body distribution can be evaluated, and the radiation dose to the bone metastases can be quantified.
In this clinical study, we will evaluate the distribution of Ra-223 using SPECT / CT accurately and quantitatively.
Optimizing the dose for each patient with SPECT/CT may lead to more effective nuclear medicine treatments in the future.